Feasibility of the Four 'A's Test (4AT) Delirium Screening Tool in Older Adults Presenting to the Emergency Department: A Rapid Systematic Review
Abstract
Delirium is a common, serious, and frequently underdiagnosed condition in older adults presenting to the emergency department (ED). The Four 'A's Test (4AT) is a brief, validated delirium screening tool requiring no specialist training or equipment, making it potentially well-suited to the fast-paced ED environment. However, evidence on its feasibility in this setting remains limited and has not been systematically synthesised. This rapid systematic review aimed to evaluate the feasibility of the 4AT, including completion time, completion rates, staff acceptability, and implementation barriers and facilitators, in EDs for adults aged 65 years and older. A rapid systematic review was conducted in accordance with PRISMA 2020 guidelines and prospectively registered on PROSPERO (CRD420261370525). PubMed, MEDLINE via Ovid, and EMBASE via Ovid were searched from January 2011 to April 2026. Two reviewers independently screened titles, abstracts, and full texts, with conflicts resolved by discussion. Primary studies reporting feasibility outcomes for the 4AT in an ED setting in adults aged ≥65 were included. Data were extracted using a standardised form and methodological quality was assessed using the Joanna Briggs Institute (JBI) critical appraisal checklist appropriate to each study design. Findings were synthesised narratively. A total of 195 records were identified across PubMed, MEDLINE, and EMBASE. Following removal of 98 duplicates, 97 unique records were screened at title…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.